

Financial Tear Sheet

Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Stock Performance

OVID (Common Stock)

| | |
|--------------------|-----------------------|
| Exchange | NASDAQ GS (US Dollar) |
| Price | \$7.40 |
| Change (%) | 0.00 (0.00%) |
| Volume | 123,474 |
| 52 Week High | \$15.93 |
| 52 Week Low | \$5.28 |
| Market Cap | \$182,054,326 |
| Rolling EPS | -4.50 |
| PE Ratio | 0 |
| Shares Outstanding | 24,601,936 |

Data as of October 20, 2017 4:00 p.m. ET



Recent Headlines

October 16, 2017

Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

October 10, 2017

Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome

October 5, 2017

Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

SEC Filings

| Filing Date | Form |
|-------------------|------|
| October 16, 2017 | 8-K |
| October 10, 2017 | 8-K |
| September 6, 2017 | 4 |
| September 6, 2017 | 3 |

Upcoming Events

There are currently no events scheduled.

Corporate Governance

| | |
|------------------------------------|--|
| Jeremy Levin, D.Phil., MB BChir | Chairman of the Board of Directors |
|------------------------------------|--|

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.